Johnson & Johnson logo

Johnson & Johnson

JNJNYSEStock Fundamentals

Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacture of products dedicated to human health and well-being. The company operates as a holding company with a diverse portfolio spanning advanced pharmaceutical therapies and medical technologies. Its core value proposition lies in delivering innovative clinical solutions across a broad range of therapeutic areas and surgical specialties.

Market Cap$557.82B
Revenue TTM$96.4B
Net Income TTM$21.0B
P/E Ratio26.51
Net Margin21.83%
EPS TTM$8.64
Free Cash Flow TTM$17.8B
Employees134.4K
CEOJoaquin Duato
CountryUnited States of America
Healthcare
Drug Manufacturers - General
SegmentsPharmaceuticals, Medical Devices, Biotechnology
Business ModelsR&D-driven manufacturing, Intellectual property licensing, B2B distribution
Most Recent EarningsApr 14, 2026 · 1 month 11 days agoQ1 2026
View report
Next EarningsJul 15, 2026 · in 2 monthsBefore Market Open · Q2 2026

Financials

Based on Q1 2026 filing

Gross Margin67.82%
ROE26.42%
D/E89.24%
Current Ratio1.03
Total Debt$72.4B
Cash$21.7B
CapEx TTM$5.1B

Gross Profit

View metric

Net Income

View metric

Operating Cash Flow

View metric

Free Cash Flow

View metric

EPS (Diluted)

View metric

Business Segments

Innovative Medicine

primary

Focuses on novel pharmaceutical therapies across immunology, oncology, neuroscience, infectious diseases, and cardiovascular metabolism. This segment drives growth through high-value prescription drugs and complex biologic treatments.

Products

DARZALEX, STELARA, REMICADE, TREMFYA, IMBRUVICA, ERLEADA, XARELTO, SPRAVATO, CARVYKTI, INVEGA SUSTENNA, OPSUMIT, UPTRAVI

Customers

Wholesalers, Retailers, Hospitals, Healthcare professionals

MedTech

major

Provides a comprehensive portfolio of medical technology solutions for cardiovascular care, orthopaedics, general and advanced surgery, and vision care. The segment emphasizes interventional solutions and enabling technologies for professional clinical use.

Products

Abiomed heart recovery technologies, Shockwave circulatory restoration products, ACUVUE contact lenses, TECNIS intraocular lenses, Mentor breast aesthetics, DePuy Synthes orthopaedic implants

Customers

Hospitals, Physicians, Nurses, Eye care professionals, Clinics

Segment Financials

Innovative Medicine — Total Assets

View metric

REMICADE — Percent Change (as a percent)

View metric

Innovative Medicine — Amortization

View metric

MEDTECH — Total Assets

View metric

MEDTECH — Percent Change (as a percent)

View metric

MEDTECH — Amortization

View metric

Business Overview

Competitive Position

A leading global healthcare entity with significant market share in oncology and immunology, characterized by a massive R&D pipeline and a dominant position in the medical device market.

Geographies

United States, Europe, Asia-Pacific, Latin America

Customer Segments

Healthcare providers, Medical distributors, Government health programs

Upstream Dependencies

Raw material suppliers, Contract research organizations, Specialized chemical providers, Biotechnology patent licensors

Downstream Customers

Pharmacy benefit managers, Governmental payers (Medicare/Medicaid), Private insurance companies, Hospital procurement networks

Johnson & Johnson logo

Johnson & Johnson FAQ

Common questions about Johnson & Johnson

Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacture of products dedicated to human health and well-being. The company operates as a holding company with a diverse portfolio spanning advanced pharmaceutical therapies and medical technologies. Its core value proposition lies in delivering innovative clinical solutions across a broad range of therapeutic areas and surgical specialties.

Johnson & Johnson (JNJ) has a market capitalization of $557.82B and trades on NYSE.

Johnson & Johnson generated $96.4B in trailing twelve-month revenue with net income of $21.0B, representing a net margin of 21.8%. Gross margin stands at 67.8%, with free cash flow of $17.8B. These figures are based on the Q1 2026 filing.

Johnson & Johnson's key competitors include Pfizer, Stryker, Merck & Co., and others. These companies compete in similar markets and product categories.

Johnson & Johnson has approximately 134,400 employees.